Dupilumab (SAR231893)

DRUG4 trials

Sponsors

Sanofi

Conditions

Dermatitis AtopicHealthy VolunteerHealthy Volunteers

Phase 1

A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants

CompletedNCT05976360

SanofiHealthy Volunteer

Start: 2014-11-02End: 2015-01-17Updated: 2023-08-04

Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults

CompletedNCT05976386

SanofiHealthy Volunteers

Start: 2021-06-08End: 2021-09-24Updated: 2025-09-19

A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.

CompletedNCT05976373

SanofiHealthy Volunteers

Start: 2015-01-05End: 2015-03-30Updated: 2023-08-04

Phase 4

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

CompletedNCT04823130

SanofiDermatitis Atopic

Start: 2021-04-22End: 2022-08-30Updated: 2025-09-16

Related Papers

508 - Dupilumab treatment normalizes intraepidermal nerve fiber density in patients with moderate-to-severe AD

British Journal of Dermatology2024-02-011 citations